| アブストラクト | Early initiation of remdesivir (RDV) is recommended to improve COVID-19 outcomes, but real-world studies describing patterns of RDV use and related outcomes among Japanese COVID-19 patients at high-risk of severe outcomes or death are limited. This claims-based cohort study included 60,165 high-risk patients hospitalized with COVID-19 between October 2021 and June 2023 using the DeSC Healthcare claims database. Patients were categorized into early-RDV (within 2 days of hospital admission), late-RDV (between day 3 and day 7), and no-RDV groups based on RDV initiation timing. Descriptive analyses were performed according to RDV groups. Of the study patients, >/=85% were very elderly (>/=75 years). Approximately 39% of patients received early RDV, 2% received late RDV, and 59% received no RDV. By day 28, the proportion of alive discharge for early-, late-, and no-RDV groups was 74.9%, 63.1%, and 71.8%, respectively. The mortality for early-, late-, and no-RDV groups was 7.7%, 8.8%, and 8.4%, respectively. Future hypothesis-driven studies with an appropriate adjustment for confounders are needed to formally evaluate the impact of RDV initiation timing on clinical outcomes in this high-risk, predominantly late-elderly population in Japan. |
|---|
| ジャーナル名 | Viruses |
|---|
| Pubmed追加日 | 2026/4/27 |
|---|
| 投稿者 | Shindo, Yuichiro; Piao, Yi; Berry, Mark; Ramroth, Heribert; Yoshida, Manami |
|---|
| 組織名 | Department of Respiratory Medicine, Nagoya University Graduate School of;Medicine, Nagoya 466-8550, Japan.;Gilead Sciences, K.K., 16/F GRAN TOKYO SOUTH TOWER, 1-9-2 Marunouchi, Chiyoda-ku,;Tokyo 100-6616, Japan.;Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94405, USA.;Gilead Sciences, EU, 2 Roundwood Ave., Uxbridge UB11 1AF, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42043268/ |
|---|
